Copyright
©The Author(s) 2021.
World J Gastrointest Pharmacol Ther. Mar 18, 2021; 12(2): 32-39
Published online Mar 18, 2021. doi: 10.4292/wjgpt.v12.i2.32
Published online Mar 18, 2021. doi: 10.4292/wjgpt.v12.i2.32
mean ± SD | P value | ||
Age | 47.9 ± 10.4 | ||
Male | 27 (54%) | ||
Treatment period (wk) | 60.8 ± 9.7 | ||
AST | BT | 82.3 ± 218.6 | < 0.001 |
AT | 23.7 ± 14.1 | ||
ALT | BT | 74.3 ± 118.1 | < 0.001 |
AT | 23.7 ± 14.1 | ||
T.Bil. | BT | 0.8 ± 0.4 | 0.024 |
AT | 0.8 ± 1 | ||
Albumin | BT | 3.9 ± 0.7 | > 0.5 |
AT | 4 ± 0.8 | ||
Creatine | BT | 1 ± 1.98 | > 0.5 |
AT | 0.8 ± 0.2 | ||
PLT | BT | 208000 ± 55000 | 0.007 |
AT | 238000 ± 78000 | ||
Ishak score | BT | 2.2 ± 1.4 | 0.002 |
AT | 1.3 ± 1.3 | ||
HAI score | BT | 7.2 ± 3.2 | < 0.001 |
AT | 4.1 ± 2.8 |
- Citation: Abayli B, Abaylı C, Gencdal G. Histopathological evaluation of long-term tenofovir disoproxil fumarate treatment in patients with hepatitis be antigen-negative chronic hepatitis B. World J Gastrointest Pharmacol Ther 2021; 12(2): 32-39
- URL: https://www.wjgnet.com/2150-5349/full/v12/i2/32.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v12.i2.32